- A couple of articles on metronomic therapy
- ARX788 possible new drug after t-dm1, t-dxd, tucatinib
- The State of the Union in Cancer Innovation
- CEA marker bone met
- Estradiol as treatment for ER+ breast cancer.
- Treatment Decision Guided by Circulating Tumor Cell Count May Improve Long-term ...
- A review of treatment options in HER2-low breast cancer and proposed treatment sequen
- Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
- A Phase I/II Trial of HER2 Vaccine–Primed ...Treatment Refractory HER2–Overexpressing
- Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatmen
- GATA3 mediates doxorubicin resistance ...
- All Relevant Subgroups With ESR1-Mutant MBC Derive PFS Benefit With Elacestrant
- Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
- Breast cancer immunotherapy: current biomarkers and the potential of in vitro assays
- Anticipating changes in the HER2 status of breast tumours with disease ...
- Immunotherapy in breast cancer: an overview of current strategies and perspectives
- Next-Generation HER2-Targeted Antibody?Drug Conjugates in Breast Cancer
- New steps on an old path: Novel estrogen receptor inhibitors in breast cancer
- Targeting Breast Cancer: An Overlook on Current Strategies
- Breast cancer highlights from 2023 - Advanced breast cancer in 2023
- Optimal Sequential Strategies for antibody drug conjugate
- How Much Do Our Thoughts Shape Our Health?
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy
- Academic Boost: Leading Online Assignment Services
- Developing Leadership Skills in Nursing